MedPath
HSA Approval

ERLOTIREL FILM COATED TABLETS 150 MG

SIN16489P

ERLOTIREL FILM COATED TABLETS 150 MG

ERLOTIREL FILM COATED TABLETS 150 MG

May 11, 2022

WELLCHEM PHARMACEUTICALS PTE LTD

WELLCHEM PHARMACEUTICALS PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantWELLCHEM PHARMACEUTICALS PTE LTD
Licence HolderWELLCHEM PHARMACEUTICALS PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

L01EB02

erlotinib

Manufacturer Information

WELLCHEM PHARMACEUTICALS PTE LTD

Reliance Life Sciences Pvt.Ltd. Plant 6

Reliance Life Sciences Pvt.Ltd. Plant 3

Active Ingredients

Erlotinib Hydrochloride eqv Erlotinib

150 mg

Erlotinib

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ERLOTIREL FILM COATED TABLETS 150 MG - HSA Approval | MedPath